Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial

被引：0
|
作者：
Hans-Joachim Schmoll
Julia Mann
Fabian Meinert
Benjamin Garlipp
Kersten Borchert
Arndt Vogel
Eray Goekkurt
Ulrich Kaiser
Heinz-Gert Hoeffkes
Jörn Rüssel
Stephan Kanzler
Thomas Edelmann
Helmut Forstbauer
Thomas Göhler
Carla Hannig
Bert Hildebrandt
Carsten Roll
Carsten Bokemeyer
Jörg Steighardt
Franziska Cygon
Stefan Ibach
Alexander Stein
Joseph Tintelnot
机构：
[1] University Clinic,Clinic for Internal Medicine IV—Hematology/Oncology
[2] Martin-Luther-University,Department of Medicine, Hematology and BMT with section Pneumology, University Cancer Center Hamburg
[3] University Medical Center Hamburg-Eppendorf,Department for Surgery
[4] Oberhavel Kliniken Oranienburg,Clinic for Gastroenterology
[5] Clinic for Oncology/Hematology Klinikum Magdeburg,Clinic for Hematology/Oncology
[6] Medical University Hannover,Tumorclinic
[7] St. Bernward Krankenhaus,Medical Clinic II
[8] Klinikum Fulda,Clinic for Gastroenterology, Hematology and Medical Oncology
[9] Leopoldina Clinic Schweinfurt,Coordination Center for Clinical Trials Halle, Medical Faculty
[10] Oncological Practice Schkeuditz,undefined
[11] Oncological Practice Rheinsieg,undefined
[12] Oncological Center Dresden,undefined
[13] Oncological Practice Bottrop,undefined
[14] Klinikum Barnim,undefined
[15] Martin-Luther-University,undefined
[16] X-act Cologne Clinical Research GmbH,undefined
来源：
British Journal of Cancer | 2024年 / 130卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：233 / 241
页数：8
相关论文
共 50 条
  • [41] SAFETY AND EFFICACY OF BEVACIZUMAB WITH FIRST-LINE FOLFIRI FOR METASTATIC COLORECTAL CANCER: SINGLE CENTER EXPERIENCE
    De Sanctis, R.
    Longo, F.
    Gori, B.
    Zivi, A.
    Del Signore, E.
    Proietti, E.
    De Filippis, L.
    Stumbo, L.
    Quadrini, S.
    Di Seri, M.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 145 - 145
  • [42] Safety and efficacy of bevacizumab with first-line FOLFIRI for metastatic colorectal cancer: Single center experience
    Longo, F.
    De Sanctis, R.
    Quadrini, S.
    Stumbo, L.
    Del Signore, E.
    Gori, B.
    De Filippis, L.
    Di Seri, M.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 91 - 92
  • [43] PRELIMINARY EFFICACY OF BEVACIZUMAB WITH FIRST LINE CHEMOTHERAPY BY FOLFOX OR FOLFIRI FOR METASTATIC COLORECTAL CANCER (MCRC): AN ALGERIAN EXPERIENCE
    Bensalem, A.
    Bouzid, K.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 : 40 - 40
  • [44] Final efficacy and safety findings from a phase II trial of capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC)
    Patt, Yehuda
    Liebmann, James
    Diamandidis, Dimitrios
    Eckhardt, Gail
    Javle, Milind
    Justice, Glen
    Keiser, Leroy W.
    Lee, Fa-Chyi
    Miller, William
    Lin, Edward
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 88 - 88
  • [45] Second line FOLFOX4 and bevacizumab for metastatic colorectal cancer: Real life efficacy and predictive factors
    Lewandowski, T.
    Biernacka, R.
    Chmielowiec, M.
    Gryziak, M.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [46] BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
    Ubago, R.
    Castillo, M. A.
    Flores, S.
    Beltran, C.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A435 - A435
  • [47] Effect of bevacizumab combined with first-line chemotherapy on metastatic colorectal cancer
    Xiong, Lifeng
    Lou, Yinmei
    Wang, Lin
    [J]. AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (04): : 3609 - 3617
  • [48] FOLFOX7 regimen in the first-line treatment of metastatic colorectal cancer
    Koca, Dogan
    Unal, Olcun Umit
    Oztop, Ilhan
    Yilmaz, Ugur
    [J]. TURKISH JOURNAL OF GASTROENTEROLOGY, 2014, 25 (02): : 198 - 204
  • [49] Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort
    Annie Fourrier-Réglat
    Denis Smith
    Magali Rouyer
    Jacques Bénichou
    Rosine Guimbaud
    Yves Bécouarn
    Olivier Bernard
    Pernelle Noize
    Nicholas Moore
    Alain Ravaud
    [J]. Targeted Oncology, 2014, 9 : 311 - 319
  • [50] Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort
    Fourrier-Reglat, Annie
    Smith, Denis
    Rouyer, Magali
    Benichou, Jacques
    Guimbaud, Rosine
    Becouarn, Yves
    Bernard, Olivier
    Noize, Pernelle
    Moore, Nicholas
    Ravaud, Alain
    [J]. TARGETED ONCOLOGY, 2014, 9 (04) : 311 - 319
12345